Deutsche Bank’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.97M | Buy |
171,488
+33,487
| +24% | +$459K | ﹤0.01% | 1681 |
|
|
2026
Q1 | $1.72M | Buy |
138,001
+19,750
| +17% | +$265K | ﹤0.01% | 1850 |
|
|
2025
Q4 | $1.49M | Sell |
118,251
-835,451
| -88% | -$9.56M | ﹤0.01% | 1963 |
|
|
2025
Q3 | $9.55M | Buy |
953,702
+358,707
| +60% | +$3.22M | ﹤0.01% | 1068 |
|
|
2025
Q2 | $4.81M | Buy |
594,995
+289,374
| +95% | +$2.18M | ﹤0.01% | 1258 |
|
|
2025
Q1 | $2.56M | Buy |
305,621
+171,735
| +128% | +$1.43M | ﹤0.01% | 1583 |
|
|
2024
Q4 | $1.06M | Buy |
133,886
+45,066
| +51% | +$378K | ﹤0.01% | 2204 |
|
|
2024
Q3 | $739K | Buy |
88,820
+21,064
| +31% | +$165K | ﹤0.01% | 2263 |
|
|
2024
Q2 | $430K | Buy |
67,756
+8,821
| +15% | +$56K | ﹤0.01% | 2403 |
|
|
2024
Q1 | $357K | Buy |
58,935
+1,664
| +3% | +$9.38K | ﹤0.01% | 2508 |
|
|
2023
Q4 | $348K | Sell |
57,271
-1,454
| -2% | -$6.48K | ﹤0.01% | 2572 |
|
|
2023
Q3 | $248K | Sell |
58,725
-231,242
| -80% | -$862K | ﹤0.01% | 2636 |
|
|
2023
Q2 | $899K | Sell |
289,967
-19,071
| -6% | -$40.6K | ﹤0.01% | 2053 |
|
|
2023
Q1 | $430K | Buy |
309,038
+15,558
| +5% | +$31K | ﹤0.01% | 2586 |
|
|
2022
Q4 | $584K | Buy |
293,480
+689
| +0.2% | +$1.54K | ﹤0.01% | 2358 |
|
|
2022
Q3 | $591K | Buy |
292,791
+508
| +0.2% | +$1.42K | ﹤0.01% | 2283 |
|
|
2022
Q2 | $929K | Sell |
292,283
-6,846
| -2% | -$24.8K | ﹤0.01% | 2235 |
|
|
2022
Q1 | $1.25M | Sell |
299,129
-6,433
| -2% | -$28.5K | ﹤0.01% | 2212 |
|
|
2021
Q4 | $1.46M | Buy |
305,562
+244,030
| +397% | +$1.22M | ﹤0.01% | 2196 |
|
|
2021
Q3 | $328K | Sell |
61,532
-1,843
| -3% | -$9.28K | ﹤0.01% | 3295 |
|
|
2021
Q2 | $324K | Sell |
63,375
-4,347
| -6% | -$24.7K | ﹤0.01% | 3498 |
|
|
2021
Q1 | $456K | Sell |
67,722
-6,034
| -8% | -$33.4K | ﹤0.01% | 3159 |
|
|
2020
Q4 | $337K | Sell |
73,756
-7,061
| -9% | -$31.3K | ﹤0.01% | 3162 |
|
|
2020
Q3 | $313K | Sell |
80,817
-107,026
| -57% | -$458K | ﹤0.01% | 2939 |
|
|
2020
Q2 | $895K | Buy |
187,843
+123,663
| +193% | +$509K | ﹤0.01% | 2295 |
|
|
2020
Q1 | $224K | Sell |
64,180
-117,688
| -65% | -$498K | ﹤0.01% | 2888 |
|
|
2019
Q4 | $875K | Buy |
181,868
+68,009
| +60% | +$236K | ﹤0.01% | 2445 |
|
|
2019
Q3 | $329K | Buy |
113,859
+24,085
| +27% | +$84K | ﹤0.01% | 2897 |
|
|
2019
Q2 | $641K | Sell |
89,774
-171,700
| -66% | -$1.76M | ﹤0.01% | 3115 |
|
|
2019
Q1 | $3.7M | Buy |
261,474
+42,772
| +20% | +$565K | ﹤0.01% | 2059 |
|
|
2018
Q4 | $2.96M | Buy |
218,702
+21,999
| +11% | +$396K | ﹤0.01% | 2147 |
|
|
2018
Q3 | $4.37M | Sell |
196,703
-3,069
| -2% | -$64.6K | ﹤0.01% | 2295 |
|
|
2018
Q2 | $3.28M | Buy |
+199,772
| New | +$3.51M | ﹤0.01% | 2620 |
|
Other funds holding AMRX
TGA
RCMNY
Deutsche Bank's AMRX Position: Q2 2026 in Review
Deutsche Bank increased its Amneal Pharmaceuticals (AMRX) stake by 24% in Q2 2026, buying an estimated $459K and bringing the position to 171,488 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1681.
Deutsche Bank first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. The position peaked at $9.55M in Q3 2025. 308 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Deutsche Bank held 171,488 shares of Amneal Pharmaceuticals worth $2.97M as of Q2 2026.
- Deutsche Bank bought 33,487 Amneal Pharmaceuticals shares in Q2 2026, an estimated $459K.
- Amneal Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1681 holding.
- Deutsche Bank first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Deutsche Bank's Amneal Pharmaceuticals position peaked at $9.55M in Q3 2025.
- 308 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.